We are building an experienced, thoughtful Leadership Team bringing together scientific & clinical expertise, comprehensive industry experience and a track record of success.
Chief Executive Officer
Chris Nowers is a senior global biopharma executive with significant experience in the areas of cell therapy and immuno-oncology. He joined ONK Therapeutics as CEO in October 2020.
Michael O’Dwyer MD
Founder and Chief Scientific Officer
Michael O’Dwyer is an experienced Clinician Scientist with a strong track record in clinical and translational research in blood cancers and has been involved in the clinical drug development of many ground-breaking treatments. He is a Founder of ONK Therapeutics and has been the company’s CSO since its inception in 2015.
Chief Operating Officer
Mary is an accomplished, senior biopharma executive with extensive experience across all aspects of global drug development and operational management. She joined ONK Therapeutics as COO in January 2021.
Head of R&D, USA
Rohit Duggal is an experienced industry-research leader who specializes in establishing and advancing cell therapy and immuno-oncology platforms for product development. He joined ONK therapeutics as Head of R&D, USA in October 2020.
George Schlich is a UK and European Patent Attorney, a founding director of ONK Therapeutics and has been responsible from the start for the IP portfolio.